Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PADI1 | Q9ULC6 | 2/20 | 0.41 |
| ▸ | PADI4 | Q9UM07 | 2/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 2/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL485946 | 0.84 | ANPEP (0.42) | SIGMAR1ANPEPERAP2MEN1KMT2A | |
| SCHEMBL7361998 | 0.83 | TSHR (0.38) | SMN1; SMN2KMT2AALDH1A1DPP4 | |
| SCHEMBL31138116 | 0.83 | USP2 (0.47) | SMN1; SMN2ANPEPMEN1KMT2AALDH1A1 | |
| SCHEMBL31503050 | 0.82 | MEN1 (0.39) | PADI1PADI4CHRM5CHRM3SMN1; SMN2 | |
| SCHEMBL31503051 | 0.82 | MEN1 (0.39) | PADI1PADI4CHRM5CHRM3SMN1; SMN2 | |
| SCHEMBL7501509 | 0.80 | CHRM2 (0.40) | CHRM3ALDH1A1KDM4EDPP4 | |
| SCHEMBL18205337 | 0.80 | SMN1; SMN2 (0.38) | PADI1PADI4CHRM5CHRM3SMN1; SMN2 | |
| SCHEMBL28706595 | 0.80 | SMN1; SMN2 (0.38) | PADI1PADI4CHRM5CHRM3SMN1; SMN2 | |
| SCHEMBL939405 | 0.74 | CHRM5 (0.41) | PADI1PADI4CHRM5CHRM3SMN1; SMN2 | |
| SCHEMBL26912060 | 0.74 | CHRM5 (0.41) | PADI1PADI4CHRM5CHRM3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| EP-4737898-A2 | SEPARATION AND ISOLATION OF NUCLEIC ACIDS USING AFFINITY LIGANDS BOUND TO A SOLID SURFACE | EMP Biotech GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4304842-B1 | METHOD FOR MAKING PHOTOFUNCTIONAL CONTACT LENSES | ALCON INC (CH) | 2026-05-06 | — | — | EP | disclosed |
| US-20260042797-A1 | SEPARATION AND ISOLATION OF NUCLEIC ACIDS USING AFFINITY LIGANDS BOUND TO A SOLID SURFACE | EMP BIOTECH GMBH (DE) | 2026-02-12 | — | — | US | disclosed |
| US-12344633-B2 | Separation and isolation of nucleic acids using affinity ligands bound to a solid surface | EMP BIOTECH GMBH (DE) | 2025-07-01 | — | — | US | disclosed |
| US-12297323-B2 | Polysiloxane vinylic crosslinkers with high refractive index | ALCON INC. (CH) | 2025-05-13 | — | — | US | disclosed |
| EP-4314118-B1 | POLYSILOXANE VINYLIC CROSSLINKERS WITH HIGH REFRACTIVE INDEX | ALCON INC (CH) | 2025-04-30 | — | — | EP | disclosed |
| US-12285922-B2 | Method for making photofunctional contact lenses | ALCON INC. (CH) | 2025-04-29 | — | — | US | disclosed |
| US-12247169-B2 | Method for making photochromic contact lenses | ALCON INC. (CH) | 2025-03-11 | — | — | US | disclosed |
| EP-4313567-B1 | METHOD FOR MAKING PHOTOCHROMIC CONTACT LENSES | ALCON INC (CH) | 2025-01-29 | — | — | EP | disclosed |
| US-7981885-B2 | N-[3-substituted piperazino] alkylphenothiazines; antiproliferative agents, apoptotic agents; 5-HT receptor antagonists | IMMUNE CONTROL INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7923445-B2 | 10-{3-[4-(2-Amino)ethylpiperazinyl]propyl}2-trifluoromethylphenothiazine and analogues and derivatives; antiproliferative agents; serotonin receptor antagonists; apoptosis in activated lymphocytes, including T, B, and and mylenoma cells; asthma; antiarthritic agents; rheumatic diseeases | IMMUNE CONTROL, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| EP-2089391-A2 | BRUTON'S TYROSINE KINASE ACTIVITY PROBE AND METHOD OF USING | PHARMACYCLICS, INC. (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-2061788-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES RELATED TO ACTIVATED LYMPHOCYTES | Immune Control, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080214501-A1 | Bruton's tyrosine kinase (Btk) activity probe comprising a Btk inhibitor moiety, a reporter moiety, and a linker moiety that links the inhibitor moiety to the reporter moiety; probes are used to characterize and develop Btk-selective inhibitors intended for therapeutic use | PHARMACYCLICS, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080132697-A1 | Novel compositions for treatment of diseases related to activated lymphocytes | IMMUNE CONTROL, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080125415-A1 | Novel methods for treatment of diseases related to activated lymphocytes | IMMUNE CONTROL, INC. (US) | 2008-05-29 | — | — | US | disclosed |
| WO-2008054827-A2 | BRUTON'S TYROSINE KINASE ACTIVITY PROBE AND METHOD OF USING | PHARMACYCLICS, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008027521-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES RELATED TO ACTIVATED LYMPHOCYTES | IMMUNE CONTROL, INC. (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344633-B2 | Separation and isolation of nucleic acids using affinity ligands bound to a solid surface | ADAR, SSBP1, POLRMT | PADI1 3441/4885PADI4 3409/4885CHRM5 3581/4885 |
| US-20080214501-A1 | Bruton's tyrosine kinase (Btk) activity probe comprising a Btk inhibitor moiety, a reporter moiety, and a linker moiety that links the inhibitor moiety to the reporter moiety; probes are used to characterize and develop Btk-selective inhibitors intended for therapeutic use | BTK, SYK, LYN | PADI1 677/4885PADI4 783/4885CHRM5 4827/4885 |
| US-20260042797-A1 | SEPARATION AND ISOLATION OF NUCLEIC ACIDS USING AFFINITY LIGANDS BOUND TO A SOLID SURFACE | POLM, SSBP1, POLRMT | PADI1 1602/4885PADI4 2213/4885CHRM5 1344/4885 |
| US-20080132697-A1 | Novel compositions for treatment of diseases related to activated lymphocytes | NFATC1, CD4, TPH1 | PADI1 3701/4885PADI4 2989/4885CHRM5 361/4885 |
| US-20080125415-A1 | Novel methods for treatment of diseases related to activated lymphocytes | HTR5A, TPH1, TPH2 | PADI1 2762/4885PADI4 1737/4885CHRM5 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.